LivaNova Announces CE Mark for PureFlex Arterial Cannulae Line for Conventional Cardiac Surgery

LivaNova PLC has achieved CE Mark for its new PureFlex line of adult arterial cannulae. Engineered to improve the critical link between the patient and extracorporeal circulation, PureFlex cannulae provide curved and straight tip options. The phthalate (DEHP)-free flexible tubing features exceptional transparency and a wire-reinforcement spring to deliver flexibility without kinking.
 
“Our decades-long commitment to excellence in cannulation continues with the addition of the new PureFlex cannulae to our robust portfolio. We call it ‘the cannulae that can,’” said Alistair Simpson, LivaNova’s general manager of its Cardiac Surgery business franchise. “Now with CE Mark, we are eager to offer this high-quality line of cannulae to cardiac surgery teams and skilled surgeons, benefitting the full range of adult conventional cardiac surgery patients and delivering the best care possible.”
 
The PureFlex family of adult arterial cannulae meets diverse clinical needs and is another example of LivaNova’s efforts to transform medical innovation into meaningful solutions. In addition to PureFlex, LivaNova offers a portfolio of conventional cannulae with a wide range of tips and sizes.
 
LivaNova PLC is a global medical technology company whose technologies and treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, United Kingdom, and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston, Texas, and Clamart (France), respectively.